Cited by 392CAR-T cell therapy researchMultiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Open access

Smith, Eric L., Harrington, Kim, Staehr, Mette, Masakayan, Reed, Jones, Jon, Long, Thomas J., Ng, Khong Y., Ghoddusi, Majid, Purdon, Terence J., Wang, Xiuyan, Do, Trevor, Pham, Minh Thu, Brown, Jessica M., De Larrea, Carlos Fernandez, Olson, Eric, Peguero, Elizabeth, Wang, Pei, Liu, Hong, Xu, Yiyang, Garrett-Thomson, Sarah C., Almo, Steven C., Wendel, Hans-Guido, Riviere, Isabelle, Liu, Cheng, Sather, Blythe, Brentjens, Renier J.·2019·Science Translational Medicine

DOI 10.1126/scitranslmed.aau7746PMC PMC7508042

Open this paper in CoChat — free account

Abstract

GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aau7746

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citation
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citation
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,363
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,279
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 14×
“R. Gardner, D. Wu, S. Cherian, M. Fang, L.-A. Hanafi, O. Finney, H. Smithers, M. C. Jensen, S. R. Riddell, D. G. Maloney, C. J. Turtle, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.”
Influential
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Brudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 792

Flagged first, then by citations

Show all 35 references

1 of the 35 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

A. D. Cohen, A. L. Garfall, E. A. Stadtmauer, S. F. Lacey, E. Lancaster, D. T. Vogl, B. M. Weiss, D. E. Ambrose, A. M. Nelson, F. Chen, G. Plesa, I. Kulikovskaya, V. Gonzalez, M. Gupta, R. M. Young, K. Dengel, L. O’keefe, S. Le, C. Richardson, R. E. Isaacs, J. J. Melenhorst, B. L. Levine, C. H. June, M. C. Milone, Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 130, 505 (2017).

Sorted by citations

Items 101–200 of 392

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Neri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 38
Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
Jurgens, E. M., Firestone, R., Chaudhari, J., Hosszu, K., Devlin, S. M., Shah, U. A., Landa, J., McAvoy, D. P., Lesokhin, A. M., Korde, N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01785 · Cited by 36
Self-citation
A Preclinical Embryonic Zebrafish Xenograft Model to Investigate CAR T Cells in Vivo
Pascoal, S., Salzer, B., Scheuringer, E., Wenninger-Weinzierl, A., Sturtzel, C., Holter, W., Taschner‐Mandl, S., Lehner, M., & Distel, M. (2020) · Cancers · doi:10.3390/cancers12030567 · Cited by 37
Structure and function of therapeutic antibodies approved by the US FDA in 2023
Strohl, W. R. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbae007 · Cited by 37
Antibodies expand the scope of angiotensin receptor pharmacology
Skiba, M. A., Sterling, S. M., Rawson, S., Zhang, S., Xu, H., Jiang, H., Nemeth, G. R., Gilman, M. S. A., Hurley, J. D., Shen, P., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01620-6 · Cited by 36
Analysis of causes for poor persistence of CAR-T cell therapy in vivo
Kong, Y., Tang, L. Y., You, Y., Li, Q., & Zhu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1063454 · Cited by 36
Future of CAR T cells in multiple myeloma
Wudhikarn, K., Mailankody, S., & Smith, E. L. (2020) · Hematology · doi:10.1182/hematology.2020000111 · Cited by 35
Self-citation
The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies
Khan, T. H., Muhammad, N., Tarique, M., Usmani, D., Naz, H., & Sarode, A. Y. (2024) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-024-00055-4 · Cited by 33
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma
Eckmann, J., Fauti, T., Biehl, M., Zabaleta, A., Blanco, L., Lelios, I., Gottwald, S., Rae, R., Lechner, S., Bayer, C., et al. (2024) · Blood · doi:10.1182/blood.2024025987 · Cited by 35
Facts and Hopes in Multiple Myeloma Immunotherapy
Sperling, A. S., & Anderson, K. C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3600 · Cited by 34
Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation
Guo, T., Ma, D., & Lu, T. K. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00236 · Cited by 33
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
van de Donk, N. W. C. J., O’Neill, C. A., de Ruijter, M. E. M., Verkleij, C. P. M., & Zweegman, S. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000983 · Cited by 32
T cells in cancer: mechanistic insights and therapeutic advances
Pu, J., Liu, T., Zhou, Y., Chen, M., Fu, X., Wan, Y., Wang, J., Chen, B., Sharma, A., Lukacs‐Kornek, V., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00807-w · Cited by 33
Car-T Treatment for Hematological Malignancies
Atrash, S., Bano, K., Harrison, B. W., & Abdallah, A.-O. A. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001290 · Cited by 32
Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
Deming, F., & Sun, J. M. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12910 · Cited by 31
Novel immunotherapies in multiple myeloma – chances and challenges
Rasche, L., Wäsch, R., Munder, M., Goldschmidt, H., & Raab, M. S. (2021) · Haematologica · doi:10.3324/haematol.2020.266858 · Cited by 32
Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
Shin, H. G., Yang, H. R., Yoon, A., & Lee, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105686 · Cited by 35
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions
Labanca, C., Martino, E. A., Vigna, E., Bruzzese, A., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., Morabito, F., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14353 · Cited by 33
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Su, C. T., & Ye, J. C. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01109-y · Cited by 30
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
Choi, T., & Kang, Y. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108007 · Cited by 30
Talquetamab in multiple myeloma
Liu, L., & Krishnan, A. Y. (2023) · Haematologica · doi:10.3324/haematol.2023.283931 · Cited by 29
Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Nasiri, F., Kozani, P. S., Salem, F., Kancha, M. M., Shokoohi, S. D., & Kozani, P. S. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03697-y · Cited by 30
Myeloma: next generation immunotherapy
Cohen, A. D. (2019) · Hematology · doi:10.1182/hematology.2019000068 · Cited by 29
Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
Dhakal, B., Hari, P., Usmani, S. Z., & Hamadani, M. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01023-w · Cited by 29
Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update
Jahandar-Lashaki, S., Farajnia, S., Faraji-Barhagh, A., Hosseini, Z., Bakhtiyari, N., & Rahbarnia, L. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01195-6 · Cited by 28
A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
Andrea, A. E., Chiron, A., Sarrabayrouse, G., Bessoles, S., & Hacein‐Bey‐Abina, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1459818 · Cited by 28
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Merz, M., Dima, D., Hashmi, H., Ahmed, N., Stölzel, F., Holderried, T. A. W., Fenk, R. R., Müller, F., Tovar, N., Oliver‐Caldés, A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01197-2 · Cited by 27
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
Xia, J., Sun, Q., Zhou, D., Li, H., Wang, Y., Qi, Y., Cao, J., Yan, Z., Li, D., Cheng, H., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00048-1 · Cited by 27
Self-citation
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells
Kasap, C., Izgutdina, A., Patiño-Escobar, B., Kang, A. S., Chilakapati, N., Akagi, N., Manoj, A., Johnson, H. A., Rashid, T., Werner, J., et al. (2025) · Blood · doi:10.1182/blood.2024025536 · Cited by 29
GPRC5D as a novel immunotherapeutic target in multiple myeloma
Nath, K., Costa, B. A., & Mailankody, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00735-4 · Cited by 27
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Mohan, M., Oekelen, O. V., Akhtar, O. S., Cohen, A. D., & Parekh, S. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432204 · Cited by 27
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Braun, A., Gouni, S., Pulles, A. E., Strati, P., Minnema, M. C., & Budde, L. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433516 · Cited by 26
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
Marofi, F., Tahmasebi, S., Rahman, H. S., Kaigorodov, D., Markov, A. A., Yumashev, A. V., Shomali, N., Chartrand, M. S., Pathak, Y. V., Mohammed, R. N., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02283-z · Cited by 28
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors
Zhang, G., Bai, M., Du, H., Yuan, Y., Wang, Y., Fan, W., Zhu, H., Wu, D., He, P., & Xue, B. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s519616 · Cited by 26
Immunotherapy for Multiple Myeloma
Tamura, H., Ishibashi, M., Sunakawa, M., & Inokuchi, K. (2019) · Cancers · doi:10.3390/cancers11122009 · Cited by 25
CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
Rodríguez‐Otero, P., Prósper, F., Piérola, A. A., Paiva, B., & Miguel, J. F. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113577 · Cited by 26
Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021
Demel, I., Bago, J., Hájek, R., & Jelı́nek, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.17235 · Cited by 25
Antibody drug conjugates for the treatment of multiple myeloma
Leong, S., Lam, H. P. J., Kirkham, Z., & Popat, R. (2022) · American Journal of Hematology · doi:10.1002/ajh.26750 · Cited by 26
Anti–PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers
Eichholz, K., Fukazawa, Y., Peterson, C. W., Haeseleer, F., Medina, M., Hoffmeister, S. T., Duell, D. M., Varco-Merth, B. D., Dross, S., Park, H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169309 · Cited by 25
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Lin, C. (.-T., Tariq, M., Ullah, F., Sannareddy, A., Khalid, F., Abbas, H., Bader, A., Samaras, C., Valent, J., Khouri, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116192 · Cited by 25
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models
Pillarisetti, K., Yang, D., Luistro, L. L., Yao, J., Smith, M. L., Vulfson, P., Testa, J. S., Ponticiello, R. P., Brodeur, S. R., Heidrich, B. J., et al. (2025) · Blood · doi:10.1182/blood.2025030027 · Cited by 24
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
Stikvoort, A., van der Schans, J., Sarkar, S., Poels, R., Ruiter, R. W. J., Naik, J., Yuan, H., de Bruijn, J. D., van de Donk, N. W. C. J., Zweegman, S., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000596 · Cited by 25
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 25
Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
Hosny, M., Verkleij, C. P. M., van der Schans, J., Frerichs, K. A., Mutis, T., Zweegman, S., & van de Donk, N. W. C. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194593 · Cited by 24
Targeting GPRC5D for multiple myeloma therapy
Zhou, D., Wang, Y., Chen, C., Li, Z., Xu, K., & Zhao, K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01611-z · Cited by 23
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115674 · Cited by 23
Prediction of the Risk of Alopecia Areata Progressing to Alopecia Totalis and Alopecia Universalis: Biomarker Development with Bioinformatics Analysis and Machine Learning
Zhang, T., & Nie, Y. (2022) · Dermatology · doi:10.1159/000515764 · Cited by 23
Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
Füchsl, F., & Krackhardt, A. M. (2022) · Cells · doi:10.3390/cells11030410 · Cited by 24
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
Pu, J., Liu, T., Sharma, A., Jiang, L., Wei, F., Ren, X., Schmidt‐Wolf, I. G. H., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00576-6 · Cited by 23
Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
Laheij, A. M. G. A., & van de Donk, N. W. C. J. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08233-0 · Cited by 22
Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma
Huang, H., Wu, H., & Hu, Y. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900351 · Cited by 22
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
Hosen, N. (2019) · Cancers · doi:10.3390/cancers11122024 · Cited by 23
The Cancer-Immunity Cycle in Multiple Myeloma
Casey, M., & Nakamura, K. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s305432 · Cited by 24
Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity
Sun, Y., Yang, X., Yang, S., Lyu, Y., Zhang, B., Liu, K., Li, N., Cui, J.-C., Huang, G.-X., Liu, C.-L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01686-z · Cited by 21
Self-citation
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Jin, C., Chen, R., Fu, S., Zhang, M., Teng, Y., Yang, T., Song, F., Feng, J., Hong, R., Cui, J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010687 · Cited by 22
Therapeutics to harness the immune microenvironment in multiple myeloma
Ignatz-Hoover, J. J., & Driscoll, J. J. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.23 · Cited by 21
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
Parrondo, R. D., Ailawadhi, S., & Cerchione, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394048 · Cited by 21
Targeted Therapies for Multiple Myeloma
Leow, C. C.-Y., & Low, M. S. Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050334 · Cited by 21
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
Schinke, C., Rodríguez‐Otero, P., van de Donk, N. W. C. J., Lipe, B. C., Lavi, N., Rasche, L., Parekh, S. S., Oekelen, O. V., Vishwamitra, D., Skerget, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016613 · Cited by 20
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
Jelinek, T., Žihala, D., Zabaleta, A., Kostopoulos, I. V., Souček, O., Venglár, O., Moreno, C., Fotiou, D., Radova, E., Tamariz‐Amador, L., et al. (2025) · Blood · doi:10.1182/blood.2025029572 · Cited by 20
SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents
Madduri, D., Dhodapkar, M. V., Lonial, S., Jagannath, S., & Cho, H. J. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.08.002 · Cited by 20
Chimeric antigen receptor T-cell therapy for multiple myeloma
Wang, Z., Chen, C., Wang, L., Jia, Y., & Qin, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050522 · Cited by 21
Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma
Wachsmann, T. L. A., Meeuwsen, M. H., Remst, D. F. G., Buchner, K., Wouters, A. K., Hagedoorn, R. S., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010410 · Cited by 22
An engineering strategy to target activated EGFR with CAR T cells
Dobersberger, M., Sumesgutner, D., Zajc, C. U., Salzer, B., Laurent, E., Emminger, D., Sylvander, E., Lehner, E., Teufl, M., Seigner, J., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100728 · Cited by 20
Updates on CAR T cell therapy in multiple myeloma
Nasiri, F., Asaadi, Y., Mirzadeh, F., Abdolahi, S., Molaei, S., Piri‐Gavgani, S., & Rahbarizadeh, F. (2024) · Biomarker Research · doi:10.1186/s40364-024-00634-5 · Cited by 20
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Lu, Q., Li, H., Wu, Z., Zhu, Z., Zhang, Z., Yang, D., & Tong, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02512-6 · Cited by 19
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
Fu, B., Liu, R., Gao, G., Lin, Z., & He, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433774 · Cited by 20
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Holstein, S. A., Al-Kadhimi, Z. S., Costa, L. J., Hahn, T., Hari, P., Hillengaß, J., Jacob, A. P., Munshi, N. C., Oliva, S., Pasquini, M. C., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.09.015 · Cited by 19
Immunotherapy of Multiple Myeloma: Promise and Challenges
Abramson, H. N. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306103 · Cited by 19
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Lee, H., Ahn, S., Gonzales, G. A., Leblay, N., Barakat, E., Greening, D., Colarusso, P., Canton, J., Benaoudia, S., Hasheminasabgorji, E., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04175-8 · Cited by 18
T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies
Rallis, K. S., Hillyar, C., Sideris, M. C., & DAVIES, J. K. (2021) · Anticancer Research · doi:10.21873/anticanres.14871 · Cited by 21
Resistance and recurrence of malignancies after CAR-T cell therapy
Zeng, W., & Zhang, P. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112971 · Cited by 18
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
Harush, O., Asherie, N., Kfir‐Erenfeld, S., Adler, G., Barliya, T., Assayag, M., Gatt, M. E., Stepensky, P., & Cohen, C. J. (2022) · Haematologica · doi:10.3324/haematol.2021.280169 · Cited by 18
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC
Kolluri, A., Li, D., Li, N., Duan, Z., Roberts, L. R., & Ho, M. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000022 · Cited by 19
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Miller, K. C., Hashmi, H., & Rajeeve, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398902 · Cited by 19
New targets and technologies for CAR-T cells
Freitag, F., Maucher, M., Riester, Z., & Hudecek, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000653 · Cited by 20
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
Yang, Z., & Wang, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002549 · Cited by 18
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
Hussain, M., Yellapragada, S. V., & Hadidi, S. A. (2023) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s272703 · Cited by 18
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
Morè, S., Corvatta, L., Manieri, V. M., Morsia, E., Poloni, A., & Offidani, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111628 · Cited by 19
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma
Gong, L., Sun, H. X., Liu, L., Sun, X., Fang, T., Yu, Z., Sui, W., Xu, J., Wang, T., Feng, F., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285099 · Cited by 17
New targets for CAR T therapy in hematologic malignancies
Savani, M., Oluwole, O. O., & Dholaria, B. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101277 · Cited by 17
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
Lagreca, I., Riva, G., Nasillo, V., Barozzi, P., Castelli, I., Basso, S., Bettelli, F., Giusti, D., Cuoghi, A., Bresciani, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095242 · Cited by 18
T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
O’Neill, C. A., & van de Donk, N. W. C. J. (2023) · eJHaem · doi:10.1002/jha2.729 · Cited by 17
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
Yee, A. J. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01091-x · Cited by 17
Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma
Setayesh, S. M., Ndacayisaba, L. J., Rappard, K. E., Hennes, V., Rueda, L. Y. M., Tang, G., Lin, P., Orlowski, R. Z., Symer, D. E., Manasanch, E. E., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00446-0 · Cited by 16
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents
Giudice, M. L. D., Galimberti, S., & Buda, G. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03559-4 · Cited by 16
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
Atrash, S., & Moyo, T. K. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242018 · Cited by 16
Diagnosis and management of bispecific T cell–engaging antibody toxicity: A primer for emergency physicians
Wattana, M. K., Rowland, J., Qdaisat, A. Z., Levavi, H., Anagnostou, T., Sanchez, L. J., Friedlander, P. A., Rohs, N. C., Lipe, D. N., & Richter, J. R. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102889 · Cited by 14
Cluster-independent marker feature identification from single-cell omics data using SEMITONES
Vlot, A. H. C., Maghsudi, S., & Ohler, U. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac639 · Cited by 14
Refining chimeric antigen receptors via barcoded protein domain combination pooled screening
Rios, X., Pardias, O., Morales, M. A., Bhattacharya, P., Chen, Y., Guo, L., Zhang, C., Pierro, E. J. D., Tian, G., Barragán, G. A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.008 · Cited by 15
PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy
Mishra, A. K., Schmidt, T. M., Martell, E. B., Chen, A. S., Dogru, R. E., Hematti, P., & Callander, N. S. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.11.014 · Cited by 14
Beyond BCMA: newer immune targets in myeloma
Tan, M. S. Y., Chen, Y.-X., & Smith, E. L. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010856 · Cited by 12
Self-citation
Bispecific antibody targets and therapies in multiple myeloma
Rees, M. J., Abdallah, N., Yohannan, B., & Gonsalves, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424925 · Cited by 16
Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens
Rieger, L., Irlinger, K., Füchsl, F., Tietje, M. R., Purcarea, A., Barbian, N., Faber, M., Vogelsang, C., Pfeuffer, L., Stotz, S., et al. (2025) · Blood · doi:10.1182/blood.2024027616 · Cited by 16
Constitutive activation mechanism of a class C GPCR
Shin, J. W., Park, J., Jeong, J., Lam, J. H., Qiu, X., Wu, D., Kim, K., Lee, J., Robinson, C. V., Hyun, J., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01224-7 · Cited by 14
Dual-antigen–targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape
van de Donk, N. W. C. J., Sonneveld, P., & Einsele, H. (2026) · Blood · doi:10.1182/blood.2025032536 · Cited by 13
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
D’Agostino, M., Rota‐Scalabrini, D., Belotti, A., Bertamini, L., Arigoni, M., Sabbata, G. D., Pietrantuono, G., Pascarella, A., Tosi, P., Pisani, F., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01075-x · Cited by 13
CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies
Marhelava, K., Krawczyk, M., Firczuk, M., & Fidyt, K. (2022) · Cells · doi:10.3390/cells11111804 · Cited by 14
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
Mann, H., & Comenzo, R. L. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s305429 · Cited by 15
Road testing new CAR design strategies in multiple myeloma
Rana, P. S., Murphy, E. V., Kort, J., & Driscoll, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957157 · Cited by 14

Authors: Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., Do, T., Pham, M. T., Brown, J. M., De Larrea, C. F., Olson, E., Peguero, E., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., Almo, S. C., Wendel, H.-G., Riviere, I., Liu, C., Sather, B., & Brentjens, R. J.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Juno Therapeutics (United States) (US)
Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sloan Kettering Institute, New York, NY 10065, USA.
Eureka Therapeutics (United States) (US)
Albert Einstein College of Medicine (US)
Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eureka Therapeutics, Emeryville, CA 94608, USA.
Corresponding author: Brentjens, Renier J.
ORCID: Smith, Eric L.
Staehr, Mette
Masakayan, Reed
Jones, Jon
Ng, Khong Y.
Ghoddusi, Majid
Purdon, Terence J.
Wang, Xiuyan
Brown, Jessica M.
Peguero, Elizabeth
Garrett-Thomson, Sarah C.
Almo, Steven C.
Wendel, Hans-Guido
Sather, Blythe
Brentjens, Renier J.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2019-03-27
Volume: 11
Issue: 485
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aau7746
PMC: PMC7508042
OpenAlex: W2923396001
Cited by: 391
References: 35
Citations by year: 2026: 31 · 2025: 55 · 2024: 79 · 2023: 68 · 2022: 46 · 2021: 55 · 2020: 42 · 2019: 14
FWCI: 16.36
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (R01 CA198095, R01 HG008325)
National Cancer Institute (P30 CA008748, U54 OD020355-01, PO1 CA190174-01, P01 CA059350, P30 CA013330, R01 CA138738-05)
Multiple Myeloma Research Foundation
American Society of Hematology
Leukemia and Lymphoma Society
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: GPRC5D, multiple myeloma, CAR T-cell therapy, BCMA, scFv, phage display
MeSH terms: Receptors, Chimeric Antigen, Animals, Antibody Specificity, Humans, Multiple Myeloma, RNA, Messenger, Gene Expression, Immunotherapy, Adoptive, Mice, SCID, Mice, Inbred NOD, Xenograft Model Antitumor Assays, Receptors, G-Protein-Coupled, Cell Line, Tumor, Mice, B-Cell Maturation Antigen, Single-Chain Antibodies, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks